title: Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells.
abstract: Modulation of cell surface molecules involved in immune recognition and cellular interactions (class I major histocompatibility complex or MHC-I, B7.1 or CD80, integrin alpha4 or CD49d, tetraspanins CD9, CD81) was examined in modified B16 melanoma cells displaying either inhibited IGF-I expression or transfected OVA encoding gene. It was shown that inhibiting IGF-I expression or inserting OVA encoding gene did not lead to modification relevant to the presence of MHC-I or B7.1. However downregulation of tetraspanin CD9 was observed in modified IGF-I but not in OVA encoding gene inserted melanoma cells. Expression of tetraspanin CD81 and integrin alpha4/CD49d remained unchanged. Inoculated into syngeneic recipients, the modified melanoma cells exhibited significant delayed outgrowth with a reduction in the percentage of lethal tumors observed essentially in hosts injected with inhibited IGF-I expression cells.
authors.affiliation: Laboratoire de Toxicologie, Faculté de Pharmacie, Université René-Descartes Paris-V, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Trabado
authors.forename: P
authors.initials: P
authors.lastname: Nguyen Van Binh
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Lafarge-Frayssinet
authors.forename: M
authors.initials: M
authors.lastname: Thevenin
authors.forename: F
authors.initials: F
authors.lastname: Baudouin
authors.forename: J-M
authors.initials: JM
authors.lastname: Warnet
authors.forename: H-T
authors.initials: HT
authors.lastname: Duc
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism*; D018122:B7-1 Antigen / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D016373:DNA, Antisense / Q000235:genetics; D015536:Down-Regulation / Q000187:drug effects; D018274:Electroporation / Q000379:methods; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000378:metabolism; D006921:Hygromycin B / Q000494:pharmacology; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism; D039441:Integrin alpha4 / Q000235:genetics / Q000378:metabolism; D008546:Melanoma, Experimental / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000235:genetics / Q000378:metabolism; D060225:Tetraspanin 28; D060245:Tetraspanin 29; D014162:Transfection / Q000379:methods
chemical_list: D000900:Anti-Bacterial Agents; D015703:Antigens, CD; D000954:Antigens, Surface; D018122:B7-1 Antigen; C554799:Cd81 protein, mouse; C554870:Cd9 protein, mouse; D016373:DNA, Antisense; D015395:Histocompatibility Antigens Class I; D008562:Membrane Glycoproteins; D060225:Tetraspanin 28; D060245:Tetraspanin 29; D039441:Integrin alpha4; D006921:Hygromycin B; D007334:Insulin-Like Growth Factor I; D010047:Ovalbumin